Description
Product Specifications
- Product: AOD-9604 5mg
- Compound / formulation: AOD-9604
- Labeled quantity / volume: 5mg per vial
- Physical form: White lyophilized powder
- Research focus: Metabolic Research, Lipid Metabolism, Adipocyte Biology, Growth Hormone Fragment Research
- Available batch identifiers: Green cap / black aluminum seal (submitted sample pictured in Report #219710); Amber/orange cap / red collar, lot AO5-0920 (submitted sample photo, report #238289)
- SKU: HOP-AOD-9604-5MG
- Intended classification: Laboratory research only
Independent Laboratory Testing
Green cap / black aluminum seal β Janoshik, report #219710
- Compound reported: AOD-9604
- Measured content: 5.13mg
- Purity: 99.620%
- Test date: August 20, 2026
- View laboratory report
Amber/orange cap / red collar β Janoshik, report #238289 β Batch AO5-0920
- Compound reported: AOD-9604
- Measured content: 5.45mg; 5.32mg; 5.36mg
- Purity: 99.907%; 99.909%; 99.899%
- Test date: October 5, 2026
- Verification key: ZMGU3XYESZKW
- View laboratory report
House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.
The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.
House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.
Scientific Research Background
AOD-9604 is a modified peptide based on an end region of human growth hormone. Its sequence is related to amino acids 177β191, with an additional modification. It is a distinct fragment, rather than full-length growth hormone.
Scientists have studied how this fragment affects the way fats are processed in laboratory and animal experiments.
Human studies have also examined body-weight measurements and unwanted effects. Early animal observations did not establish a weight-loss benefit in the larger human study described below. Findings need to be considered separately for the cells, animals, or people studied.
Compound details
- Research classification: Modified C-terminal human growth hormone fragment
Clinical Research Observations
1. Why did scientists investigate AOD-9604?
AOD-9604 is a fragment derived from a region of human growth hormone.
What researchers found: Laboratory and animal studies reported changes in measurements related to fat metabolism under certain experimental conditions.
Why it matters: These early findings prompted studies examining whether similar effects could be observed in humans.
2. What did larger human investigations find?
Researchers evaluated whether AOD-9604 changed body-weight outcomes compared with placebo.
What researchers found: A regulatory scientific review described a study involving approximately 500 participants in which investigators did not observe statistically significant improvements in weight loss at 12 or 24 weeks compared with placebo. These results have not been independently established in a full peer-reviewed report of that trial.
Why it matters: Negative human findings are essential context and do not support claims of established weight-loss effectiveness.
3. What is the overall scientific takeaway?
AOD-9604 has been investigated in laboratory, animal, and human research.
What researchers found: Early laboratory observations did not translate into a demonstrated weight-loss benefit in the larger human study described above.
Why it matters: Results from experimental models cannot substitute for evidence of meaningful clinical outcomes.
Published Scientific Research
Heffernan et al. (2001)
The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and Ξ²3-AR Knock-Out Mice.
Endocrinology, 142(12), 5182β5189.
https://doi.org/10.1210/endo.142.12.8522
Stier, Vos & Kenley (2013)
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.
Journal of Endocrinology and Metabolism, 3(1β2), 7β15.
https://doi.org/10.4021/jem157w
U.S. Food and Drug Administration (2024) β Regulatory Scientific Review
FDA Briefing Document: AOD-9604-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee, December 4, 2024.
https://www.fda.gov/media/183584/download
The first publication reports preclinical animal research. The second summarizes safety and tolerability findings from earlier human clinical investigations. Neither publication establishes the safety or effectiveness of the House of Peptides product.
Understanding the Research Findings
Janoshik Reports #219710 and #238289 report analytical findings for their respective submitted AOD-9604 samples. These findings do not establish the analytical status of every vial.
The research findings above concern the specific investigational materials studied. They do not establish clinical outcomes, safety, or pharmaceutical equivalence for House of Peptidesβ AOD-9604 5mg. The research product is not FDA-approved or represented as equivalent to materials used in published studies.
House of Peptides does not claim affiliation with or endorsement by the developers referenced in the research.
Research Use Notice
For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.
Reviews
There are no reviews yet.